DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Inderide (Propranolol Hydrochloride / Hydrochlorothiazide) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Inderide is indicated in the management of hypertension.

This fixed combination is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management.

DOSAGE AND ADMINISTRATION

The dosage must be determined by individual titration.

Hydrochlorothiazide can be given at doses of 12.5 to 50 mg per day when used alone. The initial dose of propranolol is 80 mg daily, and it may be increased gradually until optimal blood pressure control is achieved. The usual effective dose when used alone is 160 to 480 mg per day.

One Inderide Tablet twice daily can be used to administer up to 160 mg of propranolol and 50 mg of hydrochlorothiazide. For doses of propranolol greater than 160 mg the combination products are not appropriate, because their use would lead to an excessive dose of the thiazide component.

When necessary, another antihypertensive agent may be added gradually beginning with 50 percent of the usual recommended starting dose to avoid an excessive fall in blood pressure.

HOW SUPPLIED

Inderide 40/25

Each hexagonal-shaped, off-white, scored tablet, embossed with an “I” and imprinted with “INDERIDE 40/25,” contains 40 mg propranolol hydrochloride (Inderal®) and 25 mg hydrochlorothiazide, in bottles of 100 (NDC 0046-0484-81).

Inderide 80/25

Each hexagonal-shaped, off-white, scored tablet, embossed with an “I” and imprinted with “INDERIDE 80/25,” contains 80 mg propranolol hydrochloride (Inderal®) and 25 mg hydrochlorothiazide, in bottles of 100 (NDC 0046-0488-81).

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15°-30°C (59°-86°C). [See USP Controlled Room Temperature]

Protect from moisture, freezing, and excessive heat.

Dispense in a well-closed container as defined in the USP.

The appearance of these tablets is a registered trademark of Wyeth Pharmaceuticals.

This product’s label may have been updated. For current package insert and further product information, please visit www.wyeth.com or call our medical communications department toll-free at 1-800-934-5556.

Wyeth ®

Wyeth Pharmaceuticals Inc.
Philadelphia, PA 19101

W10487C006
ET01
Rev 01/08

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017